Michael Hallek, MD, University Hospital of Cologne, Cologne, Germany, explores why BCL-2 inhibition is a superior front-line treatment for patients with chronic lymphocytic leukemia (CLL) and highlights the benefit of combination therapy in CLL therapy, including agents such as venetoclax, obinutuzumab and ibrutinib for this indication. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).